Profound Medical Q4 Earnings Call Highlights

Core Insights - Profound Medical is set to present the first clinical outcomes from the CAPTAIN trial ahead of schedule at the EAU meeting, which could influence reimbursement decisions for their technology [1][5][8] - The company reported a 43% year-over-year increase in Q4 2025 revenue, totaling $6.0 million, but experienced a decline in gross margin to 67% [2][3][6] - Profound Medical aims to achieve over 70% recurring revenue and profitability in the $80–85 million revenue range, supported by a growing number of TULSA-PRO sites and a new BPH software module [4][16][18] Clinical Developments - The CAPTAIN trial, a multicenter randomized controlled trial, has completed recruitment and treatments, with imminent data on primary safety and quality-of-life endpoints to be presented [1][5][7] - Key endpoints include urinary incontinence rates, 90-day hospital readmissions, and time to return to work, which are critical for assessing the technology's efficacy [9][12] Financial Performance - In Q4 2025, Profound Medical reported a net loss of CAD 8.2 million, compared to a loss of CAD 4.9 million in the previous year, with cash on hand amounting to CAD 59.7 million [2][6] - Operating expenses remained stable at approximately CAD 11.4 million, indicating controlled spending despite the net loss [2] Commercial Strategy - The company ended 2025 with 78 TULSA-PRO sites and a pipeline of 110 systems, indicating strong commercial traction [4][10] - Profound Medical has confirmed Category I CPT reimbursement for 2026, enhancing its reimbursement pathway and engaging private insurers for broader coverage [11][12] Market Expansion - The introduction of a new AI software module for benign prostatic hyperplasia (BPH) is expected to significantly expand the addressable market, potentially tripling it by adding 400,000 patients annually [18][19] - International distribution agreements have been signed in Saudi Arabia and Australia, with a cautious approach to market entry through distributors rather than direct sales [19][20]